210 related articles for article (PubMed ID: 28057664)
1. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Swain SM; Schneeweiss A; Gianni L; Gao JJ; Stein A; Waldron-Lynch M; Heeson S; Beattie MS; Yoo B; Cortes J; Baselga J
Ann Oncol; 2017 Apr; 28(4):761-768. PubMed ID: 28057664
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab-associated diarrhea in HER2/neu-positive breast cancer patients: A comparison of trials to actual practice.
Yankulina O; Zullo AR; Cabral SE; Huynh JP; Hutchinson JA; Lopresti ML; Fenton MA; Berard-Collins CM
J Oncol Pharm Pract; 2020 Jun; 26(4):912-917. PubMed ID: 31631811
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Bines J; Procter M; Restuccia E; Viale G; Zardavas D; Suter T; Arahmani A; Van Dooren V; Baselga J; Clark E; Eng-Wong J; Gelber RD; Piccart M; Mobus V; de Azambuja E;
Clin Breast Cancer; 2020 Apr; 20(2):174-181.e3. PubMed ID: 31924513
[TBL] [Abstract][Full Text] [Related]
4. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Schneeweiss A; Park-Simon TW; Albanell J; Lassen U; Cortés J; Dieras V; May M; Schindler C; Marmé F; Cejalvo JM; Martinez-Garcia M; Gonzalez I; Lopez-Martin J; Welt A; Levy C; Joly F; Michielin F; Jacob W; Adessi C; Moisan A; Meneses-Lorente G; Racek T; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
Invest New Drugs; 2018 Oct; 36(5):848-859. PubMed ID: 29349598
[TBL] [Abstract][Full Text] [Related]
6. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
7. Pertuzumab for the treatment of breast cancer: a safety review.
Gao J; Swain SM
Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349
[TBL] [Abstract][Full Text] [Related]
8. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Gao JJ; Tan M; Pohlmann PR; Swain SM
Clin Breast Cancer; 2017 Feb; 17(1):76-78. PubMed ID: 27692565
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
10. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
11. Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
R Ferreira A; Ferreira S; Lambertini M; Maurer C; Martel S; Costa L; Ponde N; de Azambuja E
Eur J Cancer; 2021 Feb; 144():351-359. PubMed ID: 33388492
[TBL] [Abstract][Full Text] [Related]
12. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
13. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM
J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.
Noguchi E; Tamura K; Hattori M; Horiguchi J; Sato N; Kanatani K; Matsunaga K; Iwata H; Fujiwara Y
Breast Cancer; 2019 Jan; 26(1):39-46. PubMed ID: 30039339
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
19. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
